DSU The Mechanism of Action in Antibody Drug Lead Leukemia Cancer Cells Discussion

I’m working on a pharmacology practice test / quiz and need guidance to help me learn.

You and your colleagues at a biotech company have developed a monoclonal antibody that potently and selectively binds to CD30, which is overexpressed on the surface of myeloid leukemia cancer cells. You begin to test the mechanism of action of this antibody and find that, in vivo, it potently kills the targeted cancer cells. However, further studies indicate that while the antibody binds CD30, it does not inhibit CD30-dependent cell signaling. Finally, treating myeloid leukemia cancer cells with the antibody in vitro (in the absence of other cells found in the body) results in no appreciable cell death.

What is the mechanism of action of this new antibody drug lead? Support your conclusion by describing how you think this antibody is involving in targeted destruction of myeloid leukemia cancer cells.